Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Troglitazone (compound)

Name: troglitazone
PubChem Compound ID: 5591
Molecular formula: C24H27NO5S
Molecular weight: 441.541 g/mol
CI-991; Rezulin; GR 92132X; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; D00395; 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; Troglitazone (JAN/USAN); 2,4-thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-.
show more »
Name: troglitazone
Name (isomeric): DB00197
Drug Type: small molecule
Brand: Prelay, Romglizone, Noscal, Rezulin, Romozin, Resulin
Category: Vasodilator Agents, Hypoglycemic Agents, Antineoplastic Agents, Fibrinolytic Agents, Platelet Aggregation Inhibitors
CAS number: 97322-87-7
Indication: For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.
Troglitazone is an oral antihyperglycemic agent which acts primarily by decreasing insulin resistance. Troglitazone is used in the management of type II diabetes (noninsulin-dependent diabetes mellitus (NIDDM) also known as adult-onset diabetes). It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. T...
show more »
Mechanism of Action:
Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulin dependent glucose disposal in skeletal muscle. Its mechanism...
show more »
Absorption: Absorbed rapidly. Food increases the extent of absorption by 30% to 85%.
Protein binding: > 99% (primarily to serum albumin)
Biotransformation: A sulfate conjugate metabolite (Metabolite 1) and a quinone metabolite (Metabolite 3) have been detected in the plasma of healthy males. A glucuronide conjugate (Metabolite 2) has been detected in the urine and also in negligible amounts in the plasma. In healthy volunteers and in patients with type 2 diabetes, the steady-state concentration of Metabolite 1 is six to seven times that of troglitazone and Metabolite 3. In in vivo drug interaction studies, troglitazone has been shown to induce cytochrome P450 CYP3A4 at clinically relevant doses.
Half Life: 16-34 hours
Affected organisms: Humans and other mammals
Drug interaction:
CholestyramineDecreases the effect of troglitazone
CyclosporineTroglitazone decreases the effect of the immunosuppressant
Ethinyl EstradiolPossible loss of contracepitve effect
NorethindronePossible loss of contraceptive effect